NATCOPHARM Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > natcopharm

Technical Analysis

Technical Strength: 3.4 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 43.4. According to RSI analysis, natcopharm is technically weak. 1.0 NATCOPHARM RSI Chart
MACD (?) MACD: -0.465 and Signal Line: 2.78. According to MACD analysis, natcopharm is technically weak. 2.0 NATCOPHARM MACD Chart
Simple Moving Average (?) Price just got above it's 200-day simple moving average which is a positive signal. According to simple moving average analysis, natcopharm is facing resistance at 572 and support level is at 563.7473. 8.0 NATCOPHARM Simple Moving Average Chart
Exponential Moving Average (?) According to exponential moving average analysis, natcopharm is in a downtrend. Resistance level is at 569. 1.0 NATCOPHARM Exponential Moving Average Chart
Bollinger Bands (?) Bollinger bandwidth suggests a squeeze is happening, watch for a breakout.%b is 0.131. According to bollinger bands, natcopharm is technically weak. 3.0 NATCOPHARM Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is above 61.8% level. Support is at 563.65 Resistance levels are 572.5 and 581.35. 6.5 NATCOPHARM Fibonacci Retracement Chart
Average True Range (?) ATR: 15 NA NATCOPHARM Average True Range Chart
Average Directional Index (?) ADX is 16.3 which means NATCOPHARM is in a trading range and there is no trend. NA NATCOPHARM Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
November 15, 2019
Open Price 565.85
High Price 567.85
Low Price 560.45
Close Price 565.05
Absolute Change 4.5
Percentage Change 0.803%
Weekly Change -3%
Monthly Change -0.106%
Yearly Change -27.1%
52-week high 799.9
52-week low 480.0
Corporate Actions
ExDate Purpose
November 21, 2019 INT DIV- RE 1 PER SH
August 29, 2019 ANNUAL GENERAL MEETING
August 22, 2019 INT DIV-RS 1.25 PER SH
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)0.704
Confidence in Beta1.53%
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 15 November 2019: Deliverable Quantity:8.66e+04 NA NATCOPHARM Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 15 November 2019: Daily Volatility:0.235 NA NATCOPHARM Annualized Daily Volatility (Spot Price) Chart

Announcements

August 28, 2019 Reply to Clarification Sought NATCOPHARM: The Exchange had sought clarification from Natco Pharma Limited with respect to announcement dated 09-Aug-2019, regarding investments approved by the Board. On basis of above the Company was required to clarify following: 1. Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief). 2. Percentage of shareholding / control acquired and / or number of shares acquired; 3. Nature of consideration - whether cash consideration or share swap and details of the same; 4. Cost of acquisition or the price at which the shares are acquired; 5. Indicative time period for completion of the acquisition; 6. Brief details of any governmental or regulatory approvals required for the acquisition; 7. Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity); 8. Industry to which the entity being acquired belongs; 9. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"; 10. Name of the target entity, details in brief such as size, turnover etc. The response of the Company is attached.
August 23, 2019 Clarification NATCOPHARM:The Exchange has sought clarification from Natco Pharma Limited with respect to announcement dated 09-Aug-2019, regarding investments approved by the Board. On basis of above the Company is required to clarify following: 1. Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).
See all Announcements

Board Meetings

Date Meeting Date Purpose
November 06, 2019 November 12, 2019 Financial Results/Dividend To consider and approve the financial results for the period ended September 30, 2019 and to consider declaration of 2nd Interim Dividend, if any, for the Financial year 2019-2020
November 04, 2019 November 12, 2019 Financial Results To consider and approve the financial results for the period ended September 30, 2019
See all Board Meetings

Get Clearnifty's Android App.

Get clearnifty on Google Play
Get clearnifty on Google Play